301075 多瑞医药
已收盘 02-13 15:00:00
资讯
新帖
简况
新实控人入主后，多瑞医药一月内接连注销两家子公司
新京报 · 02-12
新实控人入主后，多瑞医药一月内接连注销两家子公司
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
多瑞医药最新公告：王庆太、曹晓兵拟要约收购公司24.30%股份
证券之星 · 02-10
多瑞医药最新公告：王庆太、曹晓兵拟要约收购公司24.30%股份
多瑞医药（301075）披露王庆太、曹晓兵要约收购公司股份的第一次提示性公告，1月30日股价下跌0.29%
证券之星 · 01-30
多瑞医药（301075）披露王庆太、曹晓兵要约收购公司股份的第一次提示性公告，1月30日股价下跌0.29%
核心产品销量及售价大幅下滑，多瑞医药2025年净利润预亏
新京报 · 01-30
核心产品销量及售价大幅下滑，多瑞医药2025年净利润预亏
多瑞医药（301075）披露2025年度业绩预告，1月29日股价下跌4.71%
证券之星 · 01-29
多瑞医药（301075）披露2025年度业绩预告，1月29日股价下跌4.71%
股市必读：1月13日多瑞医药发生1笔大宗交易 成交金额696.13万元
证券之星 · 01-14
股市必读：1月13日多瑞医药发生1笔大宗交易 成交金额696.13万元
多瑞医药（301075）披露关于要约收购提示性公告期满90日的说明，1月12日股价上涨0.41%
证券之星 · 01-12
多瑞医药（301075）披露关于要约收购提示性公告期满90日的说明，1月12日股价上涨0.41%
多瑞医药（301075）披露关于注销募集资金专项账户的公告，1月9日股价下跌1.64%
证券之星 · 01-09
多瑞医药（301075）披露关于注销募集资金专项账户的公告，1月9日股价下跌1.64%
多瑞医药（301075）披露回购股份集中竞价减持计划，12月22日股价下跌1.77%
证券之星 · 2025-12-22
多瑞医药（301075）披露回购股份集中竞价减持计划，12月22日股价下跌1.77%
多瑞医药(301075.SZ)拟出售不超104.45万股已回购股份
智通财经网 · 2025-12-19
多瑞医药(301075.SZ)拟出售不超104.45万股已回购股份
多瑞医药（301075）披露控股股东及其一致行动人协议转让股份事项取得确认书暨控制权拟发生变更的进展公告，11月24日股价上涨3.09%
证券之星 · 2025-11-24
多瑞医药（301075）披露控股股东及其一致行动人协议转让股份事项取得确认书暨控制权拟发生变更的进展公告，11月24日股价上涨3.09%
股市必读：多瑞医药（301075）11月13日董秘有最新回复
证券之星 · 2025-11-14
股市必读：多瑞医药（301075）11月13日董秘有最新回复
多瑞医药：公司自有产品尚未布局流感方面的药物
证券之星 · 2025-11-13
多瑞医药：公司自有产品尚未布局流感方面的药物
多瑞医药（301075）披露控股股东及其一致行动人签署《股份转让协议之补充协议》暨控制权拟发生变更的进展公告，11月11日股价上涨0.02%
证券之星 · 2025-11-11
多瑞医药（301075）披露控股股东及其一致行动人签署《股份转让协议之补充协议》暨控制权拟发生变更的进展公告，11月11日股价上涨0.02%
多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司
智通财经 · 2025-11-07
多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司
多瑞医药（301075）2025年三季报简析：净利润同比下降27.23%
证券之星 · 2025-10-25
多瑞医药（301075）2025年三季报简析：净利润同比下降27.23%
多瑞医药：持续提升信息披露水平
证券之星 · 2025-10-24
多瑞医药：持续提升信息披露水平
股市必读：多瑞医药(301075)股东户数0.64万户，较上期减少16.6%
中金财经 · 2025-10-24
股市必读：多瑞医药(301075)股东户数0.64万户，较上期减少16.6%
多瑞医药(301075.SZ)发布前三季度业绩，归母净亏损7972.77万元
智通财经 · 2025-10-23
多瑞医药(301075.SZ)发布前三季度业绩，归母净亏损7972.77万元
暂无数据
公司概况
公司名称：
西藏多瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-09-29
主营业务：
西藏多瑞医药股份有限公司的主营业务是化学药品制剂及中间体、原料药的研发、生产和销售。公司的主要产品是制剂、中间体、原料药。
发行价格：
27.27
{"stockData":{"symbol":"301075","market":"SZ","secType":"STK","nameCN":"多瑞医药","latestPrice":62.08,"timestamp":1770966207000,"preClose":61.89,"halted":0,"volume":516400,"delay":0,"changeRate":0.0031,"floatShares":80000000,"shares":80000000,"eps":-1.5665,"marketStatus":"已收盘","change":0.19,"latestTime":"02-13 15:00:00","open":62.14,"high":63.39,"low":61.28,"amount":32383300,"amplitude":0.0341,"askPrice":62.08,"askSize":2,"bidPrice":62,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-1.5665,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":61.89,"symbolType":"stock","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":68.08,"lowLimit":55.7,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80000000,"isCdr":false,"pbRate":8.29,"roa":"--","roe":"--","epsLYR":-0.79,"committee":-0.016393,"marketValue":4966000000,"turnoverRate":0.0065,"status":0,"floatMarketCap":4966000000},"requestUrl":"/m/hq/s/301075/tweets","defaultTab":"tweets","newsList":[{"id":"2610992190","title":"新实控人入主后，多瑞医药一月内接连注销两家子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992190","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610992190?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:42","pubTimestamp":1770867720,"startTime":"0","endTime":"0","summary":"业内认为，多瑞医药短期内接连注销子公司，一方面是子公司业绩不佳无法为母公司贡献收益，另一方面是新实控人入主后对公司业务的优化与调整。新实控人入主后，能否带领多瑞医药走出亏损，助力其发展，仍有待时间验证。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262111657492906241.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262111657492906241.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770867741168435.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770867741168435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0175","LU1064130708.USD","LU1655091616.SGD","BK0187","LU1820825898.SGD","LU2097828557.USD","LU2097828474.EUR","LU2488822045.USD","BK0012","LU2580892789.USD","LU1328615791.USD","BK0028","BK0183","LU1997244956.HKD","LU2328871848.SGD","BK0239","LU1580142542.USD","LU1997245177.USD","BK0070","LU1997245094.SGD","BK0099","300142","LU2495084118.USD","BK0196","BK0046","BK0184","LU0405327494.USD","LU1969619763.USD","BK0060","LU2097828805.USD","LU1781817850.SGD","LU1146622755.USD","BK0097","LU2148510915.USD","LU1064131003.USD","301075","BK0077","LU0405327148.USD","LU2097828631.EUR","LU2289578879.USD","600276","LU2097828714.EUR","601607","LU2580892862.HKD","BK0020","300683","BK0209","LU1255011170.USD"],"gpt_icon":0},{"id":"2610662972","title":"多瑞医药最新公告：王庆太、曹晓兵拟要约收购公司24.30%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610662972","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610662972?lang=zh_cn&edition=full","pubTime":"2026-02-10 23:00","pubTimestamp":1770735635,"startTime":"0","endTime":"0","summary":"多瑞医药(301075.SZ)公告称，王庆太、曹晓兵拟通过部分要约的方式，按照32.07元/股的价格向除崔子浩外的全体股东发出部分要约收购，初步要约比例分别为22%、2.30%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000038571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2607423000","title":"多瑞医药（301075）披露王庆太、曹晓兵要约收购公司股份的第一次提示性公告，1月30日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607423000","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607423000?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:16","pubTimestamp":1769786175,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，多瑞医药报收于62.15元，较前一交易日下跌0.29%，最新总市值为49.72亿元。多瑞医药于2026年1月30日披露《关于王庆太、曹晓兵要约收购公司股份的第一次提示性公告》。公告显示，王庆太、曹晓兵以要约方式收购多瑞医药部分股份，要约价格为32.07元/股，预定收购19,440,000股，其中王庆太拟收购17,600,000股，曹晓兵拟收购1,840,000股。截至2026年1月29日，王庆太和曹晓兵分别已有1户股东净预受对应全部拟收购股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2607097020","title":"核心产品销量及售价大幅下滑，多瑞医药2025年净利润预亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607097020","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607097020?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:28","pubTimestamp":1769761680,"startTime":"0","endTime":"0","summary":"1月29日晚间，多瑞医药发布2025年业绩预告，报告期内预计归属于上市公司股东的净利润亏损7624.49万元-9911.83万元，同比下滑21.67%-58.17%。主要销售品种醋酸钠林格注射液受集采影响销量和售价大幅下滑是当前影响业绩的主要原因之一。但从多瑞医药2025年业绩预告来看，该核心产品虽然大幅降价进入集采，但2025年销量依然大幅下降，并未实现“以价换量”，这也导致了多瑞医药2025年度主营业务收入规模及毛利水平大幅下降。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl882026130166242889471.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl882026130166242889471.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1769761717169764.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1769761717169764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["301075"],"gpt_icon":0},{"id":"2607363860","title":"多瑞医药（301075）披露2025年度业绩预告，1月29日股价下跌4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607363860","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607363860?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:44","pubTimestamp":1769697853,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，多瑞医药报收于62.33元，较前一交易日下跌4.71%，最新总市值为49.86亿元。近日，西藏多瑞医药股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润亏损7,624.49万元至9,911.83万元，较上年同期亏损增加21.67%至58.17%；扣除非经常性损益后的净利润亏损8,224.87万元至10,692.33万元。业绩下滑主要因主营产品醋酸钠林格注射液在国家集采中标后销售价格及收入大幅下降，以及子公司四川多瑞虽收入增长但仍处于亏损状态。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2603637648","title":"股市必读：1月13日多瑞医药发生1笔大宗交易 成交金额696.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603637648","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603637648?lang=zh_cn&edition=full","pubTime":"2026-01-14 03:40","pubTimestamp":1768333220,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，多瑞医药报收于55.69元，下跌0.73%，换手率1.55%，成交量1.24万手，成交额7020.52万元。当日关注点来自交易信息汇总：1月13日主力与游资资金均呈净流出，散户资金净流入644.52万元。大宗交易1月13日多瑞医药发生1笔大宗交易，成交金额696.13万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400002908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2602054631","title":"多瑞医药（301075）披露关于要约收购提示性公告期满90日的说明，1月12日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054631","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602054631?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:27","pubTimestamp":1768228033,"startTime":"0","endTime":"0","summary":"公司于近日发布《王庆太、曹晓兵关于要约收购提示性公告期满90日的说明》。公告显示，王庆太、曹晓兵及其一致行动人崔子浩拟通过协议转让方式取得多瑞医药控制权，并于2025年10月14日披露要约收购报告书摘要。截至本说明出具日，距提示性公告已满90日，协议转让股份过户已完成，124,688,160元履约保证金已存入指定账户。要约收购报告书将尽快披露，本次要约收购尚未生效，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2602374006","title":"多瑞医药（301075）披露关于注销募集资金专项账户的公告，1月9日股价下跌1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602374006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602374006?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:40","pubTimestamp":1767969628,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，多瑞医药报收于55.87元，较前一交易日下跌1.64%，最新总市值为44.7亿元。该股当日开盘57.52元，最高57.52元，最低55.42元，成交额达4373.88万元，换手率为0.98%。公司于近日发布公告称，西藏多瑞医药股份有限公司因募集资金已按规定使用完毕，为降低管理成本，决定注销全部募集资金专项账户。截至目前，8个募集资金专户均已注销，相关监管协议同步终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2593485029","title":"多瑞医药（301075）披露回购股份集中竞价减持计划，12月22日股价下跌1.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485029?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:55","pubTimestamp":1766397336,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，多瑞医药报收于50.0元，较前一交易日下跌1.77%，最新总市值为40亿元。公司近日发布公告称，西藏多瑞医药股份有限公司计划以集中竞价方式出售已回购股份，拟出售数量不超过1,044,500股，占公司总股本的1.31%，实施期限为2026年1月14日至2026年7月13日。本次出售不会导致公司总股本和控制权变化。公司已于2024年4月30日完成前述股份的回购，回购金额总计20,983,265.41元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2592169808","title":"多瑞医药(301075.SZ)拟出售不超104.45万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2592169808","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592169808?lang=zh_cn&edition=full","pubTime":"2025-12-19 19:41","pubTimestamp":1766144482,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药 公告，公司董事会审议通过了《关于回购股份集中竞价减持计划的议案》，根据公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购股份,实施期限为自本公告披露之日起15个交易日后的6个月内，本次拟出售回购股份不超过104.45万股，占公司总股本的1.31%，出售价格根据二级市场价格确定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2585498870","title":"多瑞医药（301075）披露控股股东及其一致行动人协议转让股份事项取得确认书暨控制权拟发生变更的进展公告，11月24日股价上涨3.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498870?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:21","pubTimestamp":1763994070,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，多瑞医药报收于49.1元，较前一交易日上涨3.09%，最新总市值为39.28亿元。公司近日发布公告称，西藏多瑞医药控股股东西藏嘉康及其一致行动人舟山清畅与王庆太、崔子浩、曹晓兵签署股份转让协议，拟转让公司29.60%股份。同时，王庆太、曹晓兵拟通过要约收购方式增持24.30%股份，西藏嘉康将预受要约并放弃对应股份表决权。公司已收到深交所出具的股份协议转让确认书，尚需办理过户登记，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2583313511","title":"股市必读：多瑞医药（301075）11月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2583313511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583313511?lang=zh_cn&edition=full","pubTime":"2025-11-14 04:54","pubTimestamp":1763067251,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，多瑞医药报收于55.76元，下跌3.51%，换手率3.39%，成交量2.71万手，成交额1.51亿元。董秘最新回复投资者： 您好，贵公司有没有可以用于流感方面的？感谢您对公司的关注！交易信息汇总资金流向11月13日主力资金净流出105.88万元；游资资金净流入323.46万元；散户资金净流出217.57万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400003670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2583559069","title":"多瑞医药：公司自有产品尚未布局流感方面的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559069?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019946,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药(301075)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，贵公司有没有可以用于流感方面的？多瑞医药回复：尊敬的投资者您好，公司自有产品尚未布局流感方面的药物。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2582036089","title":"多瑞医药（301075）披露控股股东及其一致行动人签署《股份转让协议之补充协议》暨控制权拟发生变更的进展公告，11月11日股价上涨0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582036089","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582036089?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:44","pubTimestamp":1762872263,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，多瑞医药报收于56.53元，较前一交易日上涨0.02%，最新总市值为45.22亿元。同日，多瑞医药发布公告称，公司控股股东西藏嘉康及其一致行动人舟山清畅与王庆太、崔子浩、曹晓兵于近日签署《股份转让协议之补充协议》，对原协议的转让价款支付安排、业绩承诺及补偿等内容进行了调整。本次权益变动后，王庆太、崔子浩、曹晓兵将成为公司新实际控制人。该事项尚需深交所合规性确认及中登公司办理过户登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2581074100","title":"多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2581074100","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581074100?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:06","pubTimestamp":1762502764,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)发布公告，根据公司经营及战略发展的需要，为优化公司总部管理职能，公司成立全资子公司西藏瑞升祥医药有限公司，注册资本200万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","301075","159938","BK1161","BK0239","09939"],"gpt_icon":0},{"id":"2578257305","title":"多瑞医药（301075）2025年三季报简析：净利润同比下降27.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578257305","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578257305?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:11","pubTimestamp":1761343878,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期多瑞医药发布2025年三季报。根据财报显示，多瑞医药净利润同比下降27.23%。截至本报告期末，公司营业总收入1.37亿元，同比下降43.07%，归母净利润-7972.77万元，同比下降27.23%。按单季度数据看，第三季度营业总收入3042.54万元，同比下降66.29%，第三季度归母净利润-3722.41万元，同比上升37.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"gpt_icon":0},{"id":"2577556066","title":"多瑞医药：持续提升信息披露水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2577556066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577556066?lang=zh_cn&edition=full","pubTime":"2025-10-24 08:45","pubTimestamp":1761266712,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药(301075)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公告原控股股东对公司2025-2027年业绩作出承诺，若未达标将现金补偿。请问公司是否会同步建立市值管理机制，如设立市值考核指标、引入专业机构、加强投资者关系管理，以保障股东利益与市场预期稳定？多瑞医药回复：尊敬的投资者，您好！公司高度重视市值管理相关工作，后续将持续提升信息披露水平，优化市值管理机制，提高投资者沟通交流质量，及时向资本市场传递公司价值。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2577555475","title":"股市必读：多瑞医药(301075)股东户数0.64万户，较上期减少16.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577555475","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577555475?lang=zh_cn&edition=full","pubTime":"2025-10-24 08:10","pubTimestamp":1761264658,"startTime":"0","endTime":"0","summary":"来自：截至2025年9月30日，公司股东户数较6月30日减少16.6%，户均持股数量上升至1.26万股。股东户数变动截至2025年9月30日，公司股东户数为6361.0户，较6月30日减少1266.0户，减幅为16.6%。第二届监事会第二十三次会议决议公告西藏多瑞医药股份有限公司第二届监事会第二十三次会议于2025年10月22日召开，应出席监事3人，实际出席3人，会议合法有效。该事项已获董事会、监事会审议通过，尚需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251024/31732878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2577037127","title":"多瑞医药(301075.SZ)发布前三季度业绩，归母净亏损7972.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577037127","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577037127?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:17","pubTimestamp":1761211074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)发布2025年三季度报告，该公司前三季度营业收入为1.37亿元，同比减少43.07%。归属于上市公司股东的净亏损为7972.77万元。归属于上市公司股东的扣除非经常性损益的净亏损为8494.85万元。基本每股亏损为1.0064元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"多瑞医药(301075.SZ)发布前三季度业绩，归母净亏损7972.77万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771607030316,"stockEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.152},{"period":"6month","weight":0.6441},{"period":"1year","weight":2.2691},{"period":"ytd","weight":0.0404}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏多瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6361人(较上一季度减少16.60%)","perCapita":"12576股","listingDate":"2021-09-29","address":"西藏自治区昌都市卡若区经济技术开发区A区创业大道9号","registeredCapital":"8000万元","survey":" 西藏多瑞医药股份有限公司的主营业务是化学药品制剂及中间体、原料药的研发、生产和销售。公司的主要产品是制剂、中间体、原料药。","listedPrice":27.27},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"多瑞医药,301075,多瑞医药股票,多瑞医药股票老虎,多瑞医药股票老虎国际,多瑞医药行情,多瑞医药股票行情,多瑞医药股价,多瑞医药股市,多瑞医药股票价格,多瑞医药股票交易,多瑞医药股票购买,多瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}